NICE to rule on Alzheimer's drugs

Published: 3-Feb-2001


The National Institute of Clinical Excellence has decided that the cost of three drugs to treat Alzheimer's disease should be reimbursed by the UK's National Health Service. Aricept, made by Eisai and marketed in the UK by Pfizer, Exelon from Novartis, and Reminyl, sold by Shire and Janssen, are all cholinesterase inhibitors, and cost around £800;1,000 per person p.a.

You may also like